Literature DB >> 22290425

Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells.

Paloma Silva de Souza1, Flavia da Cunha Vasconcelos, Luis Felipe R Silva, Raquel Ciuvalschi Maia.   

Abstract

Multidrug resistance (MDR) is considered a multifactorial phenotype which prevents a successful clinical cancer treatment. This phenomenon is mainly associated with mechanisms that include drug extrusion by P-glycoprotein (Pgp) overexpression and resistance to apoptosis derived by members of the inhibitor of apoptosis proteins (IAPs), such as XIAP. Studies have proposed the use of compounds that are able to inhibit or modulate Pgp function, with no changes in the physiological expression of this protein. Based on that, the present study aimed to evaluate the reversal of MDR phenotype through modulation of Pgp efflux pump activity in leukemia multidrug-resistant cells, using a low dose of cyclosporine A (CsA). We showed that modulation of Pgp activity by using CsA did not induce cytotoxic effects in leukemia cells, independently of Pgp expression. However, during the modulation condition, we could observe that vincristine-induced apoptosis was significant in resistant cells, which was also coupled with decreasing expression of the inhibitor of apoptosis protein XIAP. In summary, our data suggest that CsA is able to reversing MDR phenotype in vitro, inducing sensibility in multidrug-resistant cells with no alterations in Pgp expression. These findings contribute to our knowledge for the circumvention of MDR in cancer cells and could be helpful for new treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22290425     DOI: 10.1007/s13277-012-0323-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  49 in total

1.  The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance.

Authors:  Gergely Szakács; Kevin G Chen; Michael M Gottesman
Journal:  Cancer Biol Ther       Date:  2004-04-29       Impact factor: 4.742

Review 2.  Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1.

Authors:  V M Rumjanek; G S Trindade; K Wagner-Souza; M C de-Oliveira; L F Marques-Santos; R C Maia; M A Capella
Journal:  An Acad Bras Cienc       Date:  2001-03       Impact factor: 1.753

3.  Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins).

Authors:  Monica Notarbartolo; Melchiorre Cervello; Luisa Dusonchet; Antonella Cusimano; Natale D'Alessandro
Journal:  Cancer Lett       Date:  2002-06-06       Impact factor: 8.679

4.  The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.

Authors:  E C Spoelstra; H V Westerhoff; H M Pinedo; H Dekker; J Lankelma
Journal:  Eur J Biochem       Date:  1994-04-01

5.  Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.

Authors:  Flavia C Vasconcelos; Karina L Silva; Paloma Silva de Souza; Luiz Felipe R Silva; Arthur Moellmann-Coelho; Claudete E Klumb; Raquel Ciuvalschi Maia
Journal:  Cytometry B Clin Cytom       Date:  2010-12-02       Impact factor: 3.058

6.  Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.

Authors:  Jettie J F Muris; Saskia A G M Cillessen; Wim Vos; Inge S van Houdt; J Alain Kummer; Johan H J M van Krieken; N Mehdi Jiwa; Patty M Jansen; Hanneke C Kluin-Nelemans; Gert J Ossenkoppele; Chad Gundy; Chris J L M Meijer; Joost J Oudejans
Journal:  Blood       Date:  2004-12-02       Impact factor: 22.113

7.  Expression of the IAPs in multidrug resistant tumor cells.

Authors:  Monica Notarbartolo; Melchiorre Cervello; Paola Poma; Luisa Dusonchet; Maria Meli; Natale D'Alessandro
Journal:  Oncol Rep       Date:  2004-01       Impact factor: 3.906

8.  siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells.

Authors:  Dae Won Kim; Kyung-Ok Kim; Mike J Shin; Jung Hee Ha; Sung Wook Seo; Jay Yang; Francis Y Lee
Journal:  Mol Cancer       Date:  2009-05-15       Impact factor: 27.401

9.  P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.

Authors:  T Illmer; M Schaich; U Platzbecker; J Freiberg-Richter; U Oelschlägel; M von Bonin; S Pursche; T Bergemann; G Ehninger; E Schleyer
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

10.  Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.

Authors:  L Wang; A Giannoudis; S Lane; P Williamson; M Pirmohamed; R E Clark
Journal:  Clin Pharmacol Ther       Date:  2007-06-13       Impact factor: 6.875

View more
  5 in total

1.  HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1.

Authors:  Gisela Caceres; Robert W Robey; Lubomir Sokol; Kathy L McGraw; Justine Clark; Nicholas J Lawrence; Said M Sebti; Michael Wiese; Alan F List
Journal:  Cancer Res       Date:  2012-07-03       Impact factor: 12.701

2.  Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin.

Authors:  Kwang-Youn Kim; Sang-Hun Kim; Sun-Nyoung Yu; Suel-Ki Park; Hyeun-Deok Choi; Hak-Sun Yu; Jae-Hoon Ji; Young-Kyo Seo; Soon-Cheol Ahn
Journal:  Mol Med Rep       Date:  2015-04-16       Impact factor: 2.952

3.  Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type.

Authors:  Paloma Silva de Souza; André L S Cruz; João P B Viola; Raquel C Maia
Journal:  Cancer Sci       Date:  2014-12-15       Impact factor: 6.716

4.  The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.

Authors:  Gabriela Nestal de Moraes; Paloma Silva Souza; Fernanda Casal de Faria Costas; Flavia Cunha Vasconcelos; Flaviana Ruade Souza Reis; Raquel Ciuvalschi Maia
Journal:  Leuk Res Treatment       Date:  2012-04-24

Review 5.  Yeast ABC proteins involved in multidrug resistance.

Authors:  Agata Piecuch; Ewa Obłąk
Journal:  Cell Mol Biol Lett       Date:  2013-12-02       Impact factor: 5.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.